Pluristem - Model PLX-PAD - Cells Exhibit Regenerative Potential
PLX-PAD cells exhibit regenerative potential due to their capacity to release factors in response to chemical distress signals from tissues that have been damaged by muscle trauma or inflammation. These therapeutic factors trigger the body’s repair mechanisms and stimulate tissue renewal, differentiation and modulation of immune-mediated inflammation. PLX-PAD cells also modulate the immune system, which plays a central role in the body’s response to injuries.
PLX-PAD is currently in a Phase III multinational clinical trial in muscle recovery following surgery for hip fracture, and in Phase II clinical trials for the treatment of severe COVID-19 cases complicated by ARDS. In addition, an investigator-initiated Phase I/II trial is being conducted with PLX-PAD by Tel Aviv Sourasky Medical Center (Ichilov Hospital) for the treatment of steroid-refractory chronic graft versus host disease (cGvHD)